Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2

Anti-Cancer Drugs

Volumn 23, Issue 2, 2012, Pages 239-246

  Servitja, Sonia ^a   Ramos, Manuel ^b   Gil, Miguel ^c   Sánchez Rovira, Pedro ^d   Vázquez Estevez, Sergio ^e   Virizuela, José Antonio ^f   García Estevez, Laura ^g   Velasco, Amalia ^h   Tusquets, Ignacio ^a  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c Centro Oncologico de Galicia   (Spain)

^d Hospital General de Jaen   (Spain)

^e HOSPITAL XERAL CALDE   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^g Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^h HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

docetaxel; human epidermal growth factor receptor 2; metastatic breast cancer; trastuzumab

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPERTRANSAMINASEMIA; LOADING DRUG DOSE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; TAXOIDS; UP-REGULATION;

EID: 84855235615     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834e2fe4     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249.
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18:581-592. (Pubitemid 46359643)
3. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998; 352:930-942.
4. Jones SE. Metastatic breast cancer: The treatment challenge. Clin Breast Cancer 2008; 8:224-233. (Pubitemid 351962143)
5. Buzdar AU. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist 2003; 8:335-341. (Pubitemid 36934482)
6. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998; 16:3439-3460. (Pubitemid 28481644)
7. Aapro MS. Combining new agents with anthracyclines in metastatic breast cancer: An overview of recent findings. Semin Oncol 1999; 26:17-21. (Pubitemid 29153676)
8. Chan S, Friedrichs K, Noel D, Pinter T, Van BS, Vorobiof D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17:2341-2354. (Pubitemid 29368232)
9. Colozza M, de AE, Personeni N, Lebrun F, Piccart MJ, Cardoso F. Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. Oncologist 2007; 12:253-270. (Pubitemid 46556792)
10. Slamon DJ, Clark GM,Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182. (Pubitemid 17231334)
11. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-712. (Pubitemid 19147683)
12. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-2648. (Pubitemid 29415219)
13. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719-726. (Pubitemid 34111379)
14. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792. (Pubitemid 32222155)
15. Pegram MD, Lopez A, Konecny G, Slamon DJ. Trastuzumab and chemotherapeutics: Drug interactions and synergies. Semin Oncol 2000; 27:21-25. (Pubitemid 32172252)
16. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96:739-749. (Pubitemid 38771819)
17. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18:2241-2251. (Pubitemid 29186925)
18. Leyland-Jones B, Gelmon K, Ayoub JP, Arnold A, Verma S, Dias R, et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003; 21: 3965-3971. (Pubitemid 46606210)
19. Bullock K, Blackwell K. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. Oncologist 2008; 13:515-525. (Pubitemid 351872869)
20. Fountzilas G, Tsavdaridis D, Kalogera-Fountzila A, Christodoulou CH, Timotheadou E, Kalofonos CH, et al. Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study. Ann Oncol 2001; 12:1545-1551. (Pubitemid 34065883)
21. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001; 19:2587-2595. (Pubitemid 32441364)
22. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 1800-1808. (Pubitemid 34273269)
23. Gori S, Colozza M, Mosconi AM, Franceschi E, Basurto C, Cherubini R, et al. Phase II study of weekly paclitaxel and trastuzumab in anthracyclineand taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. Br J Cancer 2004; 90:36-40. (Pubitemid 38174935)
24. Montemurro F, Choa G, Faggiuolo R, Donadio M, Minischetti M, Durando A, et al. A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. Oncology 2004; 66:38-45. (Pubitemid 38410678)
25. Sato N, Sano M, Tabei T, Asaga T, Ando J, Fujii H, et al. Combination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: A multicenter, phase-II study. Breast Cancer 2006; 13:166-171.
26. Tedesco KL, Thor AD, Johnson DH, Shyr Y, Blum KA, Goldstein LJ, et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: A multi-institutional phase II trial. J Clin Oncol 2004; 22:1071-1077. (Pubitemid 41095040)
27. Raff JP, Rajdev L, Malik U, Novik Y, Manalo JM, Negassa A, et al. Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. Clin Breast Cancer 2004; 4: 420-427. (Pubitemid 38443465)
28. Gasparini G, Gion M, Mariani L, Papaldo P, Crivellari D, Filippelli G, et al. Randomized phase II trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat 2007; 101:355-365. (Pubitemid 46169890)
29. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005; 23:4265-4274. (Pubitemid 46207001)
30. Janku F, Pribylova O, Zimovjanova M, Pazdrova G, Safanda M, Zemanova M, et al. 4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: Single institution prospective study. Bull Cancer 2004; 91:E279-E283.
31. Ghahramani P, Barton C, Leyland-Jones B. Pharmacokinetics of Herceptin administered three-weekly compared to weekly: A simulation based on data from the clinical studies. Breast 2003; 12:S40.
32. Fabi A, Metro G, Ferretti G, Giannarelli D, Di CS, Papaldo P, et al. Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. Breast 2008; 17: 499-505.
33. Von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A german breast group 26/breast international group 03-05 study. J Clin Oncol 2009; 27: 1999-2006.